Company Expects Q4 2025 Revenue of $15.9M to $16.1M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy CVRX?
Total revenue for the fourth quarter of 2025 is expected to be in the range of approximately $15.9 million to $16.1 million, representing an increase of approximately 4% to 5% over fourth quarter 2024 revenue of $15.3 million. Total revenue for full year 2025 is expected to be in the range of approximately $56.5 million to $56.7 million, representing an increase of approximately 10% to 11% over full year 2024 revenue of $51.3 million. As of December 31, 2025, the Company had a total of 252 active implanting centers, as compared to 250 as of September 30, 2025. The number of sales territories in the U.S. increased by three to a total of 53 during the three months ended December 31, 2025. As of December 31, 2025, cash and cash equivalents were $75.7 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVRX
Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is 12.67 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.640
Low
11.00
Averages
12.67
High
14.00
Current: 6.640
Low
11.00
Averages
12.67
High
14.00
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx Faces Investor Lawsuit Investigation
- Shareholder Rights Investigation: Bragar Eagel & Squire, P.C. is investigating whether CVRx has violated federal securities laws, which could impact the company's reputation and stock price significantly.
- Performance Decline Impact: On April 7, 2025, CVRx announced weaker-than-expected preliminary first-quarter results, causing its stock price to plummet from $11.54 to $6.20, a 46.3% drop, reflecting market concerns over the development of its sales representatives.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted that 25% of territory managers were hired in a short period, indicating significant adjustments in the sales team, which further raised investor concerns about performance.
- Call for Action: Bragar Eagel & Squire encourages affected investors to contact their attorneys to understand their legal rights, demonstrating the firm's commitment to protecting shareholder interests, which may influence the outcomes of future legal actions.
See More
CVRx Under Investigation for Potential Securities Violations
- Performance Decline: On April 7, 2025, CVRx reported weaker-than-expected preliminary Q1 results, causing shares to plummet from $11.54 to $6.20, a 46.3% drop, indicating issues with the development of new sales representatives and eroding market confidence.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes disclosed that 25% of territory managers were replaced in a short period, leading to further declines in performance and shares falling from $7.78 to $4.77, a 38.8% drop, highlighting significant missteps in management's sales strategy.
- Legal Investigation Initiated: Kirby McInerney LLP is investigating whether CVRx violated federal securities laws or engaged in unlawful business practices; while no lawsuit has been filed yet, this inquiry could have profound implications for the company's future legal liabilities and financial health.
- Investor Attention: With no lawsuits currently filed, investors with information or interest in the investigation are encouraged to contact the law firm, reflecting growing concern over CVRx's future and potential legal rights.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: On May 8, 2025, CVRx reported weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, exacerbating market worries about the company's future performance.
- Continued Stock Decline: Following the disappointing results, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, indicating a severe lack of investor confidence in the company's outlook.
See More
CVRx Initiates Landmark BENEFIT-HF Trial with 2,500 Patient Enrollment Target
- Trial Launch: CVRx initiated the BENEFIT-HF clinical trial on Thursday, a landmark randomized study aimed at evaluating the impact of Barostim in a significantly expanded heart failure population, targeting enrollment of 2,500 patients, making it one of the largest therapeutic cardiac device trials in heart failure.
- Device Overview: Barostim is an implantable device that delivers electrical signals to baroreceptors on the carotid artery, enhancing autonomic nervous system balance and improving heart failure symptoms; it received FDA approval in 2019 and is commercially available in the U.S. and Europe.
- Market Potential: If successful, the BENEFIT-HF trial could expand the indicated patient population for Barostim by approximately three times, significantly broadening access to this neuromodulation-based heart failure management approach, which analysts believe will greatly enhance the company's total addressable market.
- Revenue Expectations: Analysts estimate that around 1,650 patients will receive Barostim therapy during the trial, with an assumed price of $30,000 per device, potentially generating an additional $50 million in top-line revenue, further boosting CVRx's market performance.
See More
CVRx Faces Investigation After 46.3% Stock Drop Due to Salesforce Issues
- Performance Decline Reason: CVRx attributed its weak first-quarter results in 2024 to disruptions in the salesforce caused by the retirement of the previous CEO, which adversely affected market development and the adoption of Barostim therapy.
- Stock Price Volatility: On April 8, 2025, CVRx's stock plummeted 46.3%, falling $5.34 to $6.20 per share due to disappointing preliminary results, indicating strong investor concerns about the company's outlook.
- Sales Team Restructuring Impact: During the earnings call on May 9, 2025, CEO Kevin Hykes noted that 25% of territory managers were newly hired, leading to significant variability in productivity among new hires, which further exacerbated market uncertainty.
- Investor Loss Investigation: Wolf Popper LLP is investigating potential claims on behalf of investors who suffered losses trading CVRx stock, reflecting heightened market scrutiny regarding the company's governance and management transitions.
See More
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.
Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.
Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.
Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.
See More
CVRx Faces Investor Lawsuit Investigation
- Shareholder Rights Investigation: Bragar Eagel & Squire, P.C. is investigating whether CVRx has violated federal securities laws, which could impact the company's reputation and stock price significantly.
- Performance Decline Impact: On April 7, 2025, CVRx announced weaker-than-expected preliminary first-quarter results, causing its stock price to plummet from $11.54 to $6.20, a 46.3% drop, reflecting market concerns over the development of its sales representatives.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted that 25% of territory managers were hired in a short period, indicating significant adjustments in the sales team, which further raised investor concerns about performance.
- Call for Action: Bragar Eagel & Squire encourages affected investors to contact their attorneys to understand their legal rights, demonstrating the firm's commitment to protecting shareholder interests, which may influence the outcomes of future legal actions.
See More
CVRx Under Investigation for Potential Securities Violations
- Performance Decline: On April 7, 2025, CVRx reported weaker-than-expected preliminary Q1 results, causing shares to plummet from $11.54 to $6.20, a 46.3% drop, indicating issues with the development of new sales representatives and eroding market confidence.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes disclosed that 25% of territory managers were replaced in a short period, leading to further declines in performance and shares falling from $7.78 to $4.77, a 38.8% drop, highlighting significant missteps in management's sales strategy.
- Legal Investigation Initiated: Kirby McInerney LLP is investigating whether CVRx violated federal securities laws or engaged in unlawful business practices; while no lawsuit has been filed yet, this inquiry could have profound implications for the company's future legal liabilities and financial health.
- Investor Attention: With no lawsuits currently filed, investors with information or interest in the investigation are encouraged to contact the law firm, reflecting growing concern over CVRx's future and potential legal rights.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: On May 8, 2025, CVRx reported weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, exacerbating market worries about the company's future performance.
- Continued Stock Decline: Following the disappointing results, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, indicating a severe lack of investor confidence in the company's outlook.
See More
CVRx Initiates Landmark BENEFIT-HF Trial with 2,500 Patient Enrollment Target
- Trial Launch: CVRx initiated the BENEFIT-HF clinical trial on Thursday, a landmark randomized study aimed at evaluating the impact of Barostim in a significantly expanded heart failure population, targeting enrollment of 2,500 patients, making it one of the largest therapeutic cardiac device trials in heart failure.
- Device Overview: Barostim is an implantable device that delivers electrical signals to baroreceptors on the carotid artery, enhancing autonomic nervous system balance and improving heart failure symptoms; it received FDA approval in 2019 and is commercially available in the U.S. and Europe.
- Market Potential: If successful, the BENEFIT-HF trial could expand the indicated patient population for Barostim by approximately three times, significantly broadening access to this neuromodulation-based heart failure management approach, which analysts believe will greatly enhance the company's total addressable market.
- Revenue Expectations: Analysts estimate that around 1,650 patients will receive Barostim therapy during the trial, with an assumed price of $30,000 per device, potentially generating an additional $50 million in top-line revenue, further boosting CVRx's market performance.
See More
CVRx Faces Investigation After 46.3% Stock Drop Due to Salesforce Issues
- Performance Decline Reason: CVRx attributed its weak first-quarter results in 2024 to disruptions in the salesforce caused by the retirement of the previous CEO, which adversely affected market development and the adoption of Barostim therapy.
- Stock Price Volatility: On April 8, 2025, CVRx's stock plummeted 46.3%, falling $5.34 to $6.20 per share due to disappointing preliminary results, indicating strong investor concerns about the company's outlook.
- Sales Team Restructuring Impact: During the earnings call on May 9, 2025, CEO Kevin Hykes noted that 25% of territory managers were newly hired, leading to significant variability in productivity among new hires, which further exacerbated market uncertainty.
- Investor Loss Investigation: Wolf Popper LLP is investigating potential claims on behalf of investors who suffered losses trading CVRx stock, reflecting heightened market scrutiny regarding the company's governance and management transitions.
See More
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.
Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.
Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.
Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.
See More
